Background: Many anticancer drugs are only available to Australian patients at a significant cost in the time preceding approval for government subsidy. Studies indicate that many oncologists find it difficult to discuss high-cost drugs (HCDs) with patients whom they believe are unable to afford treatment, thereby limiting treatment choices. We sought to identify the information needs and communication preferences of women with breast cancer regarding HCDs.
introduction
New anticancer drugs have expanded the options for treating cancer. These specialized medications target molecular pathways within cancer cells and minimize the undesirable side-effects of traditional chemotherapies. Model examples, such as trastuzumab in the treatment of human epidermal growth factor receptor 2 (HER-2)-positive breast cancers and imatinib for metastatic gastrointestinal stromal tumors and chronic myeloid leukemia, have revolutionized the management of many malignancies, delaying disease progression and improving patient survival [1, 2] . However, new targeted therapies are often expensive and funding them within public health care systems, such as in Australia, poses significant challenges.
In Australia, new medications undergo a two-step process of approval ( Figure 1 ). The Therapeutic Goods Act provides regulatory approval for a drug, and the Pharmaceutical Benefits Advisory Committee then makes recommendations about subsidization under the Pharmaceutical Benefits Scheme (PBS) on the basis of safety, efficacy and cost-effectiveness [2, 3] . This lengthy process can result in significant delays before certain medications are subsidized and available to the public. Some expensive drugs are never listed on the PBS due to budgetary constraints, despite proven efficacy in clinical trials.
What constitutes a high-cost drug (HCD) is both culturally and socioeconomically determined. For our study purposes, a HCD was defined as an expensive anticancer drug that has not been approved for subsidization under the PBS and would represent a 'significant financial burden' for patients. The costs of unsubsidized targeted therapies are very high, often in excess of US$900/week, for example, >US$44 000/year for trastuzumab and >US$39 000/year for imatinib [2] .
Research indicates that oncologists find it difficult to discuss HCDs with patients whom they believe are unable to afford treatment. A recent Australian study found that 28%-41% of oncologists would not mention a HCD if it was unsubsidized [3] , primarily due to potential distress that knowledge of a treatment they were unable to afford would cause patients and their families. However, research shows that most patients want as much information as possible regarding treatment options [3, 4] and prefer to be involved in treatment decision making [5, 6] . A recent study investigating the attitudes of the general public regarding HCD found that, regardless of whether they could afford it, people want to be informed about high-cost treatment options [7] . Whether this desire for knowledge translates to patient populations has yet to be explored. The aim of this study was therefore to determine cancer patients' experiences and attitudes regarding HCDs.
patients and methods procedure
This study was conducted with full human research ethics committee approval. Study participants were recruited from Breast Cancer Network Australia (BCNA), a national organization representing those affected by breast cancer. E-mail invitations were sent to 317 BCNA members randomly selected from a database of women interested in breast cancer research. Potential participants replied via e-mail. Consent was obtained before the interviews.
the questionnaire
Phone interviews were conducted using a structured questionnaire. Table 2 depicts some of the core questions used to explore the fundamental themes of our study. The questionnaire was designed to examine participants' knowledge of HCDs, as well as their experiences and attitudes toward HCDs. Questions were tailored to individual HCD experience. Participants with no HCD experience were asked about hypothetical situations. Communication and decision-making style preferences were also assessed. Questions assessing knowledge of the drug approval processes in Australia were also included (Table 1) .
data analysis
A phenomenological methodology was used in the analysis of this study [8] . Following data collection, the transcribed interviews were entered into QSR-Nvivo8Ò (QSR International Pty Ltd, Doncaster, Victoria, Australia), a data management software package. The interview transcripts were initially coded into individual interview questions. Similar responses were regrouped into separate categories and the underlying themes identified. Initial themes were compared and critically analyzed by the three main researchers and overarching themes identified.
results

demographics
Of the 317 members, 51 women responded to the e-mail invitation (initial response rate of 16%). Four women later declined participation (response rate 92%). Table 2 details the demographic characteristics of study participants.
high-cost drugs
Ninety-one percent of participants defined a HCD as an outof-pocket cost of £$100/week. Of these women, 57% said £$50/ week would be high cost, although duration of treatment also influenced the women's view.
Few women (28%) in the study had discussed HCD with their oncologist. Of these women, none had declined treatment due to financial concerns.
main themes
Five overarching themes associated with HCDs and patientdoctor communication were identified: (i) control, (ii) trust, (iii) access to relevant information, (iv) fair access to treatment and (v) value. During your cancer treatment, were you asked to pay for a medication that you considered expensive? What do you think is a reasonable amount for a patient to pay for a medication? If a medication was very expensive (e.g. $1000/week), would you want to discuss it as a possible treatment option, even if you were unlikely to be able to afford it? What information is most important for you to make a decision regarding a HCD treatment option? Would you feel comfortable talking to your oncologist about your financial circumstances? How do you prefer to make decisions regarding choices about your health care?
HCD, high-cost drugs. 
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control. The desire for personal control emerged as an important theme. Ninety-six percent of participants stated they would want their oncologist to discuss a HCD regardless of their ability to afford it. Participants sought active participation in decision making regarding their treatment, either through shared decision making (59%) or autonomously after receiving advice and information from their doctor (28%). Active participation enabled women to exercise personal autonomy and maintain a sense of control during their illness, with 'choice' highlighted as an important factor in both coping and maintaining control.
At the end of the day, I need to make the decision. It's about respecting people's choices. Interview 37
However, many women felt that they did not attain the level of information or participation that they desired.
I want to take part in the decision on my own after I have the information. But you basically go to your oncologist, sit down for 10 minutes every 4 weeks, and you're told what's going to happen. There is no choice. Interview 38
Behaviors perceived to be paternalistic, such as withholding information or making assumptions regarding patients' treatment preferences, were viewed negatively. For several women with secondary cancer, this was particularly relevant. They reported subsequently learning about a drug that they felt would have been relevant to their earlier treatment, resulting in disappointment and frustration. Withholding such information denies patients the ability to exercise control over their health and had more potential to cause distress than initially disclosing the option of a HCD.
My cancer was HER2+ and I wasn't told . I probably could have taken Herceptin [trastuzumab] . Perhaps if I'd known, I wouldn't have the secondaries . doctors need to tell patients all options and let them decide for themselves. Interview 14 access to relevant information. Participants said access to 'appropriate' information was necessary to make informed decisions about treatment options that take into account their own individual needs and values. The majority of participants (85%) stated they would want to know 'everything' about treatment options. Efficacy was the most important factor (85% of women) when making decisions about a HCD. Factors relating to drug performance, quality of life, prognosis and applicability to their personal diagnosis were also identified as important. Participants acknowledged that it was difficult, but necessary, for oncologists to identify each individual's preferences for information before commencing discussions about cancer treatment.
In an ideal world, it would be great if your doctor found out how much you wanted to know before diving in. Interview 31
The majority of women identified their oncologists as the primary source of information regarding treatment. Approximately half the participants reported utilizing the internet as an additional source; however, they still wanted to discuss this information with their doctor. Women preferred both oral and written information, the opportunity to discuss options with family members, and the ability to ask questions later to ensure they had received and understood all information necessary to make an informed decision. These strategies were highlighted as enhancing their active participation in treatment decisions. Recognizing that time constraints were often a limitation, several women indicated referral to allied health professional for further discussion where appropriate.
Despite there being a general desire for information, we found a lack of understanding about the drug approval process in Australia. Two-thirds of women did not know how new medications are approved for use in Australia. Approximately 75% of the women thought the government or health department was responsible for subsidizing decisions, although they were unaware of the process. The majority of women identified cost and budgetary constraints as the primary considerations in funding decisions.
trust. Trust is the foundation of the patient-doctor relationship. Oncologists and patients make many difficult decisions over the course of cancer treatment, and it is through such interactions that patients develop confidence and trust in this relationship. Study participants described how their doctor's honesty, consistency and sharing of information about the latest breast cancer treatments helped build their relationship.
My biggest thing was building a relationship with my oncologist, building trust. This was the most important thing . I needed to trust him, that he knew best, and if I ended up with secondaries, that he would treat me through the palliative part.
Interview 25
Women who felt their oncologists were completely open and honest reported a higher sense of trust. Interestingly, women who reported trusting relationships with their doctors also assumed a less active role in decision making. These women reported greater satisfaction with information provided, being comfortable with the oncologist's recommendations, and they asked fewer questions and were less anxious about their course of management. Women who reported a lack of honest communication and collaboration were more dissatisfied with the amount of information provided by their doctor and wanted more control over decision making. Open honest communication also enabled discussion of more sensitive subjects, such as personal finances and the ability to potentially afford a HCD. The majority (89%) of women were very comfortable talking to their oncologists about their financial circumstances, given that they had discussed other sensitive topics such as sexuality, body image, family concerns, life and death.
original article Annals of Oncology fair access to treatment. Study participants felt it unfair that some treatments for life-threatening conditions were unsubsidized and therefore not accessible to all patients. Although many women felt it was reasonable for patients to contribute to the financial cost of their treatment, they held strong views that finances should not be an impediment to treatment access. Approximately one-third of the women reported the PBS co-payment of $31.50/month as a reasonable contribution for the cost of a medication, and another third indicated the contribution should be 'relative to your situation'.
It's wrong that drugs are available that are very expensive and put out of reach for a lot of people, so they're only available for the wealthy. It's criminal to have a drug that people can't get. Interview 11 Some women expressed an understanding that trade-offs are inevitable in a public system; however, others expressed frustration toward the government that certain drugs were not available in Australia, presumably due to costs.
value. Decisions about cancer treatment and HCDs are highly personal. Study participants reported that the decision to pay for a HCD was dependent on an individual's current diagnosis, social circumstances and values. Those who felt they were at lower risk were less inclined to pay for a HCD; however, when diagnosed with secondary disease, women were willing to pay for any drug if it was 'a last resort'. Women who were younger and had small children were also more likely to go ahead with treatment because ''any glimmer of hope is better than none'' (Interview 22).
Survival was a very important consideration. Generally, women were willing to pay for a HCD regardless of cost if it would possibly prolong their life or represent a 'cure'. For the women in our study who had received a HCD (n = 7), cost was not an influence in their decision; as one participant stated, if it was ''a matter of life and death, I would have done anything if it was going to save my life'' (Interview 44). Efficacy was identified as the single most important factor when considering a HCD, followed by side-effects and cost. Side-effects were particularly relevant for women with secondary breast cancer. These women valued 'quality of life' over marginal extension of overall survival and were reluctant to pay for a drug with significant side-effects.
When you reach this stage of the illness, it's more about quality than quantity. If there was a drug that made you really sick, I wouldn't want it. Interview 29 discussion
In this study, we sought to identify the needs of women with breast cancer regarding HCD information and preferred communication approaches to these discussions.
We found that the majority of women surveyed (96%) wished to be fully informed about HCDs as potential management options, regardless of their ability to potentially afford treatment. Our participants preferred a shared decisionmaking approach, and those who had established a trusting relationship with their oncologist were comfortable discussing financial information. Finally, despite a strong desire for knowledge about treatment options, we found there was still little understanding of drug approval processes in Australia among our study participants.
Despite the findings of our study, the current practice of Australian oncologists may limit the use of HCDs in treating patients with cancer. A recent study by Tattersall et al. [9] reported that oncologists find discussing HCDs with patients that may be unable to afford treatment the most difficult and stressful aspect of communication. Furthermore, Thomson et al. [3] indicated that oncologists were significantly less likely to discuss a HCD if it was not PBS listed. Oncologists were primarily concerned about the emotional impact of these discussions, especially in the event a patient was unable to afford the drug. However, our participants viewed financial matters as more of a practical issue and were more concerned with drug efficacy and quality of life. Cost rarely impacted decisions regarding HCD treatment, with the majority of women stating they would find the necessary means to pay for a HCD should they feel it was worth it. Oncologists appear to be overvaluing the perceived importance of costs, as well as the emotional aspects of discussing money.
Recently, there has been a fundamental shift regarding patient involvement in medical decision making and the traditionally dominant role of the physician, with a movement toward 'patient-centered' medicine [10, 11] . Our study results are consistent with this shift. Numerous studies have confirmed a strong desire of breast cancer patients to be active participants regarding their health care [12, 13] and the importance of being adequately informed in making collaborative decisions with their doctor [14] . The results of our study confirm these findings.
Trust was identified by women as an important factor in facilitating decision making. In a recent study by Shepherd et al. [5] , oncologists acknowledged patient trust as a key facilitator of shared decision making. Our study participants reported that a trusting relationship with their oncologist was fostered by open honest communication of all treatment options. This then enabled discussions of more sensitive subjects, such as financial circumstance. Given that 89% of study participants indicated they were comfortable discussing finances with their doctor, this indicates most patients do not find these conversations inappropriate or confronting but prefer to discuss money in a straightforward manner.
Several women reported instances of nondisclosure of HCD treatment options, which resulted in distress and a breach of trust in the relationship with their oncologist. Not only does withholding information fail to respect patient autonomy, but the outcome may also conflict with patient values and hence may not be in their best interest. The principles of control, access to relevant information and trust are clearly compromised when women are not informed of HCD options. This has the potential to cause more distress later on during the course of their cancer treatment and undermine the foundation of patient-doctor relationships.
HCD discussions are further complicated by the lack of general knowledge regarding drug approval processes. This may contribute to the difficulty of these conversations, as many patients find it unfair and do not understand why some drugs are not subsidized. In Australia, there is often an expectation Annals of Oncology original article that expenses incurred in the public system are fully subsidized, with private health insurance covering all other costs. Women in our study expressed surprise that unsubsidized drugs were also not usually covered under private insurance. This is different from a private health care system, such as that in the United States, where the public frequently pays for a large part of their health care treatment.
A strength of our study is the qualitative design. We conducted in-depth focused interviews facilitating a level of detail not possible using questionnaires. This allowed exploration of participants' thoughts in detail and clarification of responses on many important issues regarding HCDs and communication. The results should however be assessed in the light of the following limitations. Firstly, the study population was a small homogenous sample of middle-aged women with breast cancer. Our participants were members of BCNA, a prominent organization highly involved in breast cancer advocacy. Our results thus reflect opinions from a group of women who are likely to be more informed and who desire a higher level of information and involvement in their management. Recruitment via e-mail further limited diversity. The results and themes are also liable to gender bias. Further studies should explore the generalizability of our findings to all populations.
conclusions
The majority of Australian women with breast cancer wish to be informed about HCD options and want to be active participants in treatment decision making. Studies have found that oncologists find these discussions challenging and worry about potentially distressing their patients by offering a treatment option they may be unable to afford.
Our findings have important clinical applications as they provide evidence to oncologists that patients wish to be informed about HCDs, and they are comfortable discussing financial circumstances with their doctors. Furthermore, the results highlight an area of patient education that needs addressing-drug approval processes. The results of this work have already been implemented into an oncology communication training program in Australia. references
